This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
On December 13, 2018, the teaser of the film Black Antenna featuring the song "Rainier Fog" was released on Alice in Chains' official YouTube channel, with drummer Sean Kinney stating; "We've always toyed with the idea of creating videos for every song on one of our albums. Not only did we do that for Rainier Fog, it got totally out of hand and we made a whole goddamn movie. Everything that will be seen in the videos will be footage from Black Antenna to preface the complete film's release." "Rainier Fog" was released as a single on February 26, 2019. The official trailer for Black Antenna was released on Alice in Chains' YouTube Channel on February 28, 2019. Besides a 90-minute film, a 10-part web-series focused on each track from the album was planned. Episodes 1 and 2, "The One You Know" and "Rainier Fog", respectively, were released on March 7, 2019. The tenth and last episode, "All I Am", was released on July 17, 2019. The official music video for "Rainier Fog" was released on YouTube on May 15, 2019, and was co-directed by Alice in Chains and Peter Darley Miller, who also directed the band's 2013 mockumentary, AIC 23. On December 1, 2020, Alice in Chains was honored with the Founders Award from Seattle's Museum of Pop Culture. The benefit concert featured tribute performances from artists such as Ann Wilson, Korn, Metallica, Fishbone, Dallas Green, Billy Corgan, Tad Doyle, members of Soundgarden and Pearl Jam, among others. The event was made available for streaming for free and raised more than $600,000 for the museum in its first night.
When cultivated for human consumption in Western nations, insects are held to the same safety requirements as any other food. Depending on the popularity in a given location, processing might be done commercially or locally. The procedure begins with the removal of the insect's insides, albeit this step is optional. They are then dispatched to be preserved or freeze-dried, which is accomplished using hessian or polypropylene. They are transported for storage once they have been entirely preserved/dried. Insects can be frozen or ground into powders. Cricket flour is produced from freeze-dried crickets. The crickets are then cooked to facilitate processing. They are pulverized into extremely fine bits after being cooked. The freezing, baking, and drying results in a powdered dark brown flour. Insect flour is one of Whole Foods Market's banned ingredients in the U.S., with cricket flour being specifically mentioned on their paper bags.
Another common criticism is that the racemic mixture (containing both L and D enantiomers) of amino acids produced in a Miller–Urey experiment is not exemplary of abiogenesis theories, as life on Earth today uses almost exclusively L-amino acids. While it is true that Miller–Urey setups produce racemic mixtures, the origin of homochirality is a separate area in origin of life research. Recent work demonstrates that magnetic mineral surfaces like magnetite can be templates for the enantioselective crystallization of chiral molecules, including RNA precursors, due to the chiral-induced spin selectivity (CISS) effect. Once an enantioselective bias is introduced, homochirality can then propagate through biological systems in various ways. In this way, enantioselective synthesis is not required of Miller–Urey reactions if other geochemical processes in the environment are introducing homochirality. Finally, Miller–Urey and similar experiments primarily deal with the synthesis of monomers; polymerization of these building blocks to form peptides and other more complex structures is the next step of prebiotic chemistry schemes. Polymerization requires condensation reactions, which are thermodynamically unfavored in aqueous solutions because they expel water molecules. Scientists as far back as John Desmond Bernal in the late 1940s thus speculated that clay surfaces would play a large role in abiogenesis, as they might concentrate monomers.
Until May 1943, almost all penicillin was produced using the shallow-pan method pioneered by the Oxford team, but NRRL mycologist Kenneth Bryan Raper experimented with deep submergence production, in which penicillin mould was grown in a vat instead of a shallow dish. The initial results were disappointing; penicillin cultured in this manner yielded only three to four Oxford units per cubic centimetre, compared to twenty for surface cultures. He got the help of U.S. Army's Air Transport Command to search for similar mould in different parts of the world. Good moulds were found in samples from Chongqing, Bombay and Cape Town. The best sample, however, was from a cantaloupe sold in a Peoria fruit market in 1943. The mould was identified as Penicillium chrysogenum and designated as "NRRL 1951" or "cantaloupe strain". The spores may have escaped from the NRRL. Between 1941 and 1943, Moyer, Coghill and Raper developed methods for industrialized penicillin production and isolated higher-yielding strains of the Penicillium fungus. To improve upon that strain, researchers at the Carnegie Institution of Washington subjected NRRL 1951 to X-rays to produce a mutant strain designated X-1612 that produced 300 milligrams of penicillin per litre of mould culture, twice as much as NRRL 1951. In turn, researchers at the University of Wisconsin used ultraviolet radiation on X-1612 to produce a strain designated Q-176. This produced more than twice the penicillin of X-1612, but in the form of the less desirable penicillin K.
The classification of birds is a contentious issue. Sibley and Ahlquist's Phylogeny and Classification of Birds (1990) is a landmark work on the subject. Most evidence seems to suggest the assignment of orders is accurate, but scientists disagree about the relationships among the orders themselves; evidence from modern bird anatomy, fossils and DNA have all been brought to bear on the problem, but no strong consensus has emerged. Fossil and molecular evidence from the 2010s is providing an increasingly clear picture of the evolution of modern bird orders.
Sources: en.wikipedia.org
=== Genetically engineered biofactories === Various yeast species have been genetically engineered to efficiently produce various drugs, a technique called metabolic engineering. S. cerevisiae is easy to genetically engineer; its physiology, metabolism and genetics are well known, and it is amenable for use in harsh industrial conditions. A wide variety of chemical in different classes can be produced by engineered yeast, including phenolics, isoprenoids, alkaloids, and polyketides. About 20% of biopharmaceuticals are produced in S. cerevisiae, including insulin, vaccines for hepatitis, and human serum albumin.
== Pharmacokinetics == The metabolism of topically applied nitrofurazone is thought to be by 5-nitro reduction and cleavage of the -CH=N- linkage to generate a reactive species which can covalently bond to cellular macromolecules, none of the end products are thought to be antimicrobial.
Marvel Television produced multiple television series set in the MCU across broadcast, streaming, and cable. Its ABC series included Agents of S.H.I.E.L.D. (2013–2020), Agent Carter (2015–2016), and Inhumans (2017); its Netflix series included Daredevil (2015–2018), Jessica Jones (2015–2019), Luke Cage (2016–2018), Iron Fist (2017–2018), the crossover miniseries The Defenders (2017), and The Punisher (2017–2019); its young adult series included Runaways (2017–2019) streaming on Hulu and Cloak & Dagger (2018–2019) airing on Freeform; and the Hulu series Helstrom (2020) was originally intended to be the start of a planned "Adventure into Fear" franchise, but was ultimately "not tied to the MCU", according to showrunner Paul Zbyszewski.
Agouti-signaling protein is a protein that in humans is encoded by the ASIP gene. It is responsible for the distribution of melanin pigment in mammals. Agouti interacts with the melanocortin 1 receptor to determine whether the melanocyte (pigment cell) produces phaeomelanin (a red to yellow pigment), or eumelanin (a brown to black pigment). This interaction is responsible for making distinct light and dark bands in the hairs of animals such as the agouti, which the gene is named after. In other species such as horses, agouti signalling is responsible for determining which parts of the body will be red or black. Mice with wildtype agouti will be grey-brown, with each hair being partly yellow and partly black. Loss of function mutations in mice and other species cause black fur coloration, while mutations causing expression throughout the whole body in mice cause yellow fur and obesity. The agouti-signaling protein (ASIP) is a competitive antagonist with alpha-Melanocyte-stimulating hormone (α-MSH) to bind with melanocortin 1 receptor (MC1R) proteins. Activation by α-MSH causes production of the darker eumelanin, while activation by ASIP causes production of the redder phaeomelanin. This means where and while agouti is being expressed, the part of the hair that is growing will come out yellow rather than black.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.